Verrica Pharmaceuticals
Most recent annual filing: 2026-03-11
- YCANTH commercial units corporate update3Q 2026YCANTH commercial units corporate update, 3Q 2026, routine
- Verrica financingFeb 2027Verrica financing, Feb 2027, notable
- YCANTH (VP-102) common warts toplinemid-2027YCANTH (VP-102) common warts topline, mid-2027, thesis-defining
- Verrica financingJun 2027Verrica financing, Jun 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (3 active programs)
ruxotemitide
VP-315Discontinued (2)
- YCANTH — External Genital Warts · Paused for funding, not for a result: "we have paused the development of VP-102 for the treatment of external genital warts and VP-103 for the treatment of plantar warts due to our cash position" (10-K, 2026-03-11). The 10-K's pipeline graphic lists both under "Potential Future Development Opportunities", separately from "Active Product Candidates". Flips back if funding resumes.
- cantharidin — Plantar Warts · Paused for funding, not for a result: "we have paused the development of VP-102 for the treatment of external genital warts and VP-103 for the treatment of plantar warts due to our cash position" (10-K, 2026-03-11). The 10-K's pipeline graphic lists both under "Potential Future Development Opportunities", separately from "Active Product Candidates". Flips back if funding resumes.
Biotech Distilled coverage (1)
- 2026-08-24 Verrica Pharmaceuticals (VRCA) — Scientific Deep Dive for YCANTH, VP-102 in Common Warts, and VP-315 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.